Editas Medicine (EDIT) Shares Outstanding (Weighted Average) (2015 - 2025)

Editas Medicine (EDIT) has 11 years of Shares Outstanding (Weighted Average) data on file, last reported at $97.9 million in Q4 2025.

• Quarterly Shares Outstanding (Weighted Average) rose 18.86% year-over-year to $97.9 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $97.9 million (up 18.86% YoY) and the FY2025 annual result came in at $97.9 million, up 18.86% from the prior year.
• Shares Outstanding (Weighted Average) improved to $97.9 million in Q4 2025 per EDIT's latest filing, from $90.1 million in the prior quarter.
• Across five years, Shares Outstanding (Weighted Average) topped out at $97.9 million in Q4 2025 and bottomed at $66.0 million in Q1 2021.
• The 5-year median for Shares Outstanding (Weighted Average) is $72.1 million (2023), against an average of $75.8 million.
• The widest annual swing landed in 2021, when Shares Outstanding (Weighted Average) rose 21.78%; it then climbed 0.59% in 2022.
• Tracing EDIT's Shares Outstanding (Weighted Average) over 5 years: stood at $67.6 million in 2021, then advanced by 1.55% to $68.7 million in 2022, then advanced by 10.63% to $76.0 million in 2023, then increased by 8.39% to $82.3 million in 2024, then increased by 18.86% to $97.9 million in 2025.
• Per Business Quant, the three latest EDIT Shares Outstanding (Weighted Average) figures stand at $97.9 million (Q4 2025), $90.1 million (Q3 2025), and $84.4 million (Q2 2025).

Peer Comparison